Evidence map›Paper›PMID 18692117›Full record

ReviewBiochimica et biophysica acta2008

Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Megumi Iiizumi, Wen Liu, Sudha K Pai, Eiji Furuta, Kounosuke Watabe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimica et biophysica acta, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Ezrin Inhibition Up-regulates Stress Response Gene Expression.The Journal of biological chemistry · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Megumi IiizumiDepartment of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University, School of Medicine, 801 N. Rutledge Street, P.O. Box 19626, Springfield, Illinois 62794-9626, USA.
Wen Liu
Sudha K Pai
Eiji Furuta
Kounosuke Watabe

Funding

Mechanism of tumor metastases suppression by Drg1R01CA124650 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WATABE, KOUNOSUKE · 2007 to 2012
$1.1M
Functional role of tumor metastases suppressor gene, KAl1, in tumor progressionR01CA129000 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WATABE, KOUNOSUKE · 2007 to 2012
$1.0M
NCI NIH HHS R01 CA124650NCI NIH HHS R01 CA129000
6 · The paper itself

Abstract

It is well recognized that the majority of cancer related deaths is caused by metastatic diseases. Therefore, there is an urgent need for the development of therapeutic intervention specifically targeted to the metastatic process. In the last decade, significant progress has been made in this research field, and many new concepts have emerged that shed light on the molecular mechanism of metastasis cascade which is often portrayed as a succession of six distinct steps; localized invasion, intravasation, translocation, extravasation, micrometastasis and colonization. Successful metastasis is dependent on the balance and complex interplay of both the metastasis promoters and suppressors in each step. Therefore, the basic strategy of our interventions is aimed at either blocking the promoters or potentiating the suppressors in this disease process. Toward this goal, various kinds of antibodies and small molecules have been designed. These include agents that block the ligand-recepter interaction of metastasis promoters (HGF/c-Met), antagonize the metastasis-promoting enzymes (AMF, uPA and MMP) and inhibit the transcriptional activity of metastasis promoter (beta-Catenin). On the other hand, the intriguing roles of metastasis suppressors and their signal pathways have been extensively studied and various attempts have been made to potentiate these factors. Small molecules have been developed to restore the expression or mimic the function of metastasis-suppressor genes such as NM23, E-cadherin, Kiss-1, MKK4 and NDRG1, and some of them are under clinical trials. This review summarizes our current understanding of the molecular pathway of tumor metastasis and discusses strategies and recent development of anti-metastatic drugs.

Indexed as

Antineoplastic AgentsCarcinogensDrug Delivery SystemsGenes, Tumor SuppressorHumansModels, BiologicalNeoplasm MetastasisNeoplasmsSignal TransductionTumor Suppressor ProteinsAntineoplastic AgentsCarcinogensTumor Suppressor Proteins

Identifiers

PMID18692117
PMCPMC2645343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.